Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 7;22(10):1160–1168. doi: 10.1634/theoncologist.2017-0079

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Planned maximum infusion times for combined versus sequential pertuzumab and trastuzumab infusion. Pertuzumab and trastuzumab were given as sequential infusions in cycle 1 of Cohort 1 and Cohort 2. In Cohort 1, pertuzumab and trastuzumab were given as sequential infusions from cycle 2 onwards; in Cohort 2, pertuzumab and trastuzumab were given as a co‐infusion from cycle 2 onwards. ^aPertuzumab time was 0.5–1 hour; maximum time is shown [15], [16], [17].